| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 3 securities · may seek to influence control | ||||||
|
TRex Bio, Inc.
13D
TRXB · 89531N100
|
19.9% |
10/16/2026
Event 10/13/2026
|
||||
|
Scribe Therapeutics, Inc.
13D
SCTX · 811033109
|
7.3% |
7/30/2026
Event 7/23/2026
|
||||
|
Aktis Oncology, Inc.
13D
AKTSQ · 00973N102
|
11.9% |
1/15/2026
Event 1/12/2026
|
||||
| Schedule 13G · 3 securities · passive | ||||||
|
ProQR Therapeutics N.V.
13G/A
PRQR · N71542109
|
15.6% |
7/24/2026
Event 6/26/2026
|
||||
| Ionetix Corp / DE / 13G | 7.9% |
7/24/2026
Event 4/9/2026
|
||||
|
Immunocore Holdings plc
13G/A
54258D105
|
0% |
10/3/2025
Event 9/30/2025
|
||||
| ELI LILLY & Co | 0% | |||||
| Eli Lilly S.A. | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.